Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
Explore available award and grant opportunities for fellows-in-training.
Make a choice that matters
The best care starts with the best information. See videos to help answer your questions.
The ACR is accepting applications for mini curriculums, which are educational activities or curriculums to enhance the ACR Core Curriculum Outline.
Abatacept (Orencia) is often prescribed after failure of a disease-modifying anti-rheumatic agent (DMARD), like methotrexate but it can be used as first-line therapy.
Abatacept is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to stop joint deformities, therefore helping to maintain range of motion.
It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are generally tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied.
Unlike some other biologic drugs, abatacept does not block inflammatory proteins like TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communication, abatacept lessens inflammation.
Abatacept is available either in infusible or injectable form. The infusion is given intravenously (through a needle placed in a vein) at 0, 2 and 4 weeks, then monthly thereafter in your doctor's office or at an infusion center. The dosage is adjusted according to the patient’s weight. It takes 30 minutes to receive the whole infusion.
The injectable form of abatacept is injected under the skin at home once a week. It can be administered by the patient or another member of the home. Studies have shown this formulation to be as safe and effective as the infusion.
Although some patients feel relief within the first month of treatment, usually three months of continuous treatment are needed to get the full effect of the medication.
The most common side effects reported were those associated with headaches, common colds, sore throat, and nausea. Rarely, patients may develop infusion reactions while receiving abatacept including a severe allergic reaction, hives, shortness of breath, and low blood pressure. Nurses will monitor you and your vital signs throughout the infusion. Pre-medications such as Tylenol or Benadryl can be used preventively and can be discussed with your doctor.
The most important side effect is the risk of developing a serious infection, including pneumonia, tuberculosis, and others. Patients are tested for possible tuberculosis with a skin test or blood test before starting this drug. Abatacept should not be combined with another biologic drug, because the combination can increase the risk of contracting a serious infection.
It is not yet clear if the risk of cancer is higher in patients on abatacept compared to patients with other drugs. Nevertheless, larger reports should demonstrate if there is any trend of possible cancer risk.
Monitoring by your rheumatologist is necessary while taking this medication and lab monitoring may be needed periodically as well.
Using two biologic drugs (such as TNF-alpha blockers and abatacept) at the same time carries high risk of developing serious infections. Patients who have previously received another biologic drug, such as a TNF-alpha blocker, can receive abatacept after the first drug has been stopped.
Patients with diabetes mellitus should be aware that sugars in the infusion form of abatacept may cause false high blood sugar levels. You should discuss with your physician how to properly monitor this.
Patients who have been exposed to people with suspected serious infections, such as tuberculosis, should notify their doctors before taking Orencia. All patients should be tested for tuberculosis before starting abatacept. Other laboratory tests may be required as well. Patients displaying symptoms of an infection - including fever, cough, or others - should notify their doctors.
Patients should not receive live vaccines while receiving abatacept and should consult their rheumatologist before receiving a live vaccine afterwards.
Risks in pregnant women are still being studied.
Because biologics tend to be expensive, its availability may depend on your insurance formulary.
Updated March 2019 by Suleman Bhana, MD, and reviewed by the American College of Rheumatology Committee on Communications and Marketing.
This information is provided for general education only. Individuals should consult a qualified health care provider for professional medical advice, diagnosis and treatment of a medical or health condition.